Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.

Med (New York, N.Y.) - 12 Sept 2025

Satake Hironaga, Bando Hideaki, Kobayashi Shin, Yoshino Takayuki

Abstract excerpt

BRAF V600E-mutant metastatic colorectal cancer, a rare subtype with poor prognosis, has historically carried limited treatment options. Evolving approaches, including targeted combinations and investigational immunotherapy-based strategies, offer potential to improve outcomes. We highlight the evolving treatment landscape and emerging strategies for this molecularly distinct subtype.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Colorectal Neoplasms
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Precision Medicine

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 40945506
DOI: 10.1016/j.medj.2025.100811

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.PMID 40945506Read ↗

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

Emerging treatment options for BRAF-mutant colorectal cancerSemantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Metastatic colorectal cancer: current state and future directions.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

Promising New Agents for Colorectal Cancer.Semantic proximity Read ↗

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.